en
Scientific article
Review
Open access
English

Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review

Published inThe Journal of International Medical Research, vol. 47, no. 1, p. 31-43
Publication date2019
Abstract

Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy and may lead to severe visual loss. In this review, we describe the pathophysiology of DMO and review current therapeutic options such as macular laser photocoagulation, anti-vascular endothelial growth factor agents, and steroid implants with a focus on the new fluocinolone acetonide implant, ILUVIEN (R). The results of the Fluocinolone Acetonide in Diabetic Macular Edema (FAME) studies are also presented together with the results of real-world studies to support the clinical use of ILUVIEN (R) in achieving efficient resolution of DMO and improving vision and macular anatomy in this challenging group of patients.

Keywords
  • Diabetic macular oedema
  • Steroid implant
  • Fluocinolone acetonide
  • ILUVIEN
  • Diabetes
  • Anti-VEGF agents
  • Diabetic retinopathy
  • Intravitreal injections
Citation (ISO format)
MASSA, Horace et al. Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review. In: The Journal of International Medical Research, 2019, vol. 47, n° 1, p. 31–43. doi: 10.1177/0300060518816884
Main files (1)
Article (Published version)
Updates (1)
Erratum
Identifiers
ISSN of the journal0300-0605
186views
77downloads

Technical informations

Creation09/25/2020 11:35:00 AM
First validation09/25/2020 11:35:00 AM
Update time03/15/2023 10:39:50 PM
Status update03/15/2023 10:39:49 PM
Last indexation10/19/2023 1:35:49 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack